Sugi Predict

Sugi Predict / Compounds / SCHEMBL2238495

SCHEMBL2238495

SCHEMBL2238495

Cc1noc(C)c1CCCl

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.48
▸ CRHBP P24387 1/20 0.43
▸ CRHR2 Q13324 1/20 0.43
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ ALDH1A1 P00352 5/20 0.39
▸ BRD4 O60885 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ P2RX7 Q99572 3/20 0.38
▸ TAS2R8 Q9NYW2 1/20 0.38
▸ GAA P10253 1/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL189530 0.83 — —
SCHEMBL8237746 0.81 LMNA (0.44) LMNACRHBPCRHR2MEN1KMT2A
Hydrochloric Acid SCHEMBL6299008 0.81 LMNA (0.48) LMNACRHBPCRHR2MEN1KMT2A
SCHEMBL14677142 0.79 LMNA (0.43) LMNACRHBPCRHR2MEN1KMT2A
SCHEMBL30643951 0.79 — —
SCHEMBL28437236 0.79 LMNA (0.43) LMNACRHBPCRHR2MEN1KMT2A
SCHEMBL2616802 0.79 LMNA (0.43) LMNACRHBPCRHR2MEN1KMT2A
SCHEMBL1580004 0.79 LMNA (0.43) LMNACRHBPCRHR2MEN1KMT2A
SCHEMBL4193853 0.79 MEN1 (0.43) LMNACRHBPCRHR2MEN1KMT2A
SCHEMBL16429490 0.78 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11993595-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2024-05-28 — — US disclosed
CN-111592534-B New compounds 特殊治疗有限公司 2023-06-30 — — CN disclosed
US-20230052191-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2023-02-16 — — US disclosed
US-11472798-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2022-10-18 — — US disclosed
US-10961238-B2 Modulators of hedgehog (Hh) signaling pathway E-THERAPEUTICS PLC (GB) 2021-03-30 — — US disclosed
US-20200369658-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2020-11-26 — — US disclosed
US-10774078-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2020-09-15 — — US disclosed
CN-111592534-A Novel compounds 特殊治疗有限公司 2020-08-28 — — CN disclosed
CN-107001339-B Novel compounds 特殊治疗有限公司 2020-03-17 — — CN disclosed
US-20200055847-A1 MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY E-THERAPEUTICS PLC (GB) 2020-02-20 — — US disclosed
US-8853240-B2 Compounds useful for the treatment of degenerative and inflammatory diseases GALAPAGOS NV (BE) 2014-10-07 — — US disclosed
US-20140256740-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2014-09-11 — — US disclosed
EP-2361251-B1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2014-04-30 — — EP disclosed
WO-2014006402-A1 OREXIN RECEPTOR ANTAGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2014-01-09 — — WO disclosed
EP-2361251-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES Galapagos N.V. (BE) 2011-08-31 — — EP disclosed
US-20110190260-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES ALFASIGMA S.P.A. (IT) 2011-08-04 — — US disclosed
WO-2010010190-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2010-01-28 — — WO disclosed
US-20090192138-A1 COMPOUNDS BAESCHLIN DANIEL KASPAR 2009-07-30 — — US disclosed
EP-1966215-A1 CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS Novartis AG (CH) 2008-09-10 — — EP disclosed
WO-2007071738-A1 CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS NOVARTIS AG (CH) 2007-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10961238-B2 Modulators of hedgehog (Hh) signaling pathway SHH, GLI1, SMO LMNA 4872/4885CRHBP 2538/4885CRHR2 3081/4885
US-20140256740-A1 COMPOUNDS AND METHODS RORC, RORB, RORA LMNA 4009/4885CRHBP 968/4885CRHR2 334/4885
US-20200055847-A1 MODULATORS OF HEDGEHOG (HH) SIGNALLING PATHWAY SHH, GLI1, SMO LMNA 4877/4885CRHBP 2524/4885CRHR2 2930/4885
US-10774078-B2 Compounds UCHL1, UCHL3, UCHL5 LMNA 4091/4885CRHBP 4354/4885CRHR2 4647/4885
US-11472798-B2 Compounds UCHL1, UCHL3, UCHL5 LMNA 4091/4885CRHBP 4354/4885CRHR2 4647/4885
US-11993595-B2 Compounds UCHL1, UCHL3, UCHL5 LMNA 4091/4885CRHBP 4354/4885CRHR2 4647/4885
US-20090192138-A1 COMPOUNDS DPP4, DPP3, DPP8 LMNA 3764/4885CRHBP 861/4885CRHR2 897/4885
US-20110190260-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES TRAF6, IL6, TLR6 LMNA 3463/4885CRHBP 456/4885CRHR2 190/4885
US-20200369658-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 LMNA 4089/4885CRHBP 4340/4885CRHR2 4698/4885
US-20230052191-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 LMNA 4089/4885CRHBP 4340/4885CRHR2 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.